文献速递艾滋病与性传播感染

ODYSSEY试验:儿童HIV一线ART治疗失败预测因素

Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial.
PubMed 文献 · Clin Infect Dis · 2026-01-01

ODYSSEY试验显示,多替拉韦(DTG)方案优于标准方案。DTG组失败风险低于标准方案组(HR=0.47,95%CI:0.29-0.77,P=.002)。起始ART时低年龄、低年龄别BMI Z评分和低CD4%预测更高的治疗失败风险。

要点

  • DTG方案治疗失败风险显著低于标准方案(HR=0.47)
  • 起始ART时低年龄、低BMI-for-age Z评分、低CD4%预示更高失败风险
  • youngest儿童中年龄与CD4%的联合效应最强,需针对性支持

核心结论

  • DTG方案治疗失败风险低于标准方案(HR=0.47,95%CI:0.29-0.77,P=.002)。
  • 起始ART时低年龄、低BMI-for-age Z评分和低CD4%预测更高的治疗失败风险。

主要发现

  • 75例发生治疗失败(DTG组24例,标准方案组51例)。
  • BMI-for-age Z评分每增加1单位,失败风险HR=0.82(95%CI:0.70-0.96,P=.01)。
  • 非洲站点失败风险HR=2.09(95%CI:0.82-5.31,P=.09)。
  • CD4%=20时,相对于10岁,1岁HR=2.40(95%CI:1.58-3.65),5岁HR=1.30(95%CI:1.15-1.48),18岁HR=0.80(95%CI:0.72-0.89)。
  • 1岁时相对于CD4%=20,CD4%=15的HR=1.39(95%CI:1.16-1.66),CD4%=30的HR=0.52(95%CI:0.36-0.75)。

关键数值与推荐

  • DTG组与标准方案组治疗失败风险HR=0.47(95%CI:0.29-0.77,P=.002)。
  • BMI-for-age Z评分每增加1单位,HR=0.82(95%CI:0.70-0.96,P=.01)。
  • 非洲站点HR=2.09(95%CI:0.82-5.31,P=.09)。
  • CD4%=20时,1岁相对于10岁HR=2.40(95%CI:1.58-3.65),5岁HR=1.30(95%CI:1.15-1.48),18岁HR=0.80(95%CI:0.72-0.89)。
  • 1岁时相对于CD4%=20,CD4%=15的HR=1.39(95%CI:1.16-1.66),CD4%=30的HR=0.52(95%CI:0.36-0.75)。

临床怎么用

  • 对起始ART的低年龄、低BMI-for-age Z评分和低CD4%儿童应加强针对性支持。
  • 优先考虑DTG方案以降低治疗失败风险。

局限性

  • 非洲站点效应置信区间宽且P=.09,证据强度有限。
  • 为事后分析,预测因素结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on predictors of treatment failure in children starting antiretroviral therapy (ART) are limited, particularly on dolutegravir-based regimens (DTG). METHODS: ODYSSEY demonstrated superior efficacy of DTG versus standard-of-care (SOC). We assessed predictors at ART initiation of treatment failure by 96 weeks. RESULTS: Three hundred and eighty-one children started first-line ART (82% African). At ART-initiation, median age was 10.5 years (IQR: 6.5, 14.0, 67 < 3 years), CD4% 20% (IQR: 12, 28), BMI-for-age Z-score -.58 (IQR:-1.48, +.25). One hundred and eighty-nine children started DTG, 192 started SOC (91% ≥3 years started efavirenz; 79% <3 years started lopinavir). Seventy-five children experienced treatment failure (24 DTG, 51 SOC). Failure risk was lower on DTG than SOC (hazard ratio [HR] = 0.47, 95% CI: 0.29-0.77, P = .002). Lower BMI-for-age Z-score (HR = 0.82 for each unit gain, 95% CI: 0.70-0.96, P = .01) and being at an African site (HR = 2.09, 95% CI: 0.82-5.31, P = .09) were associated with higher failure risk. Risk was also higher at younger ages with the steepest increase in the youngest children and increased at lower CD4%, with a stronger CD4% effect at younger ages. At CD4% = 20, HRs relative to age 10 years were 2.40 (95% CI: 1.58-3.65) at age 1 year, 1.30 (95% CI: 1.15-1.48) at age 5 years, and 0.80 (95% CI: 0.72-0.89) at age 18 years. At age 1 year, HRs relative to CD4% = 20 were 1.39 (95% CI: 1.16-1.66) at CD4% = 15, and 0.52 (95% CI: 0.36-0.75) at CD4% = 30; at age 10, corresponding estimates were 1.07 (95% CI: 0.94-1.20) at CD4% = 15, and 0.88 (95% CI: 0.69-1.13) at CD4% = 30. CONCLUSIONS: Young age, low BMI-for-age, and low CD4% at ART initiation predicted higher risk of treatment failure and can guide targeted support.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wyncoll J, Kamolrattana R, Archary M, et al. Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial. Clin Infect Dis. 2026. PMID: 41967904. doi:10.1093/cid/ciag232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。